Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 701–800 of 1,008
Shao, L., Zhang, Y., Yang, Z., Shi, C., Yue, X., Li, C., Liu, Y., Fu, Z., Tang, C., Zhao, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads6613 · Cited by 14
“However, owing to side effects such as Fc receptor activation and complement cascade reactions, such therapies may activate local immune cells while inducing neuroinflammation, further exacerbating cognitive and memory deficits in AD patients ( 7 , 9 ).”
Hypothesis on ontogenesis and pathophysiology of Alzheimer’s disease
Schwab, E. D. P., Queiroz, R., Fiebrantz, A. K. B., Bastos, M., Bonini, J. S., & da Silva, W. C. F. N. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022rw0170 · Cited by 15
“In patients with early AD, donanemab showed better scores on cognition tests and ability to perform daily tasks than placebo at 76 weeks, although secondary endpoints were mixed.(121) More extensive and more prolonged trials are warranted to study the efficacy and safety of donanemab in AD.”
BackgroundNjavro, J. R., Vukicevic, M., Fiorini, E., Dinkel, L., Müller, S. A., Berghofer, A., Bordier, C., Kozlov, S. O., Halle, A., Buschmann, K., et al. (2022) · Cells · doi:10.3390/cells12010079 · Cited by 17
A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
Brum, W. S., Bastiani, M. A. D., Bieger, A., Therriault, J., Ferrari‐Souza, J. P., Benedet, A. L., Saha‐Chaudhuri, P., Souza, D. O., Ashton, N. J., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12270 · Cited by 13
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
Dresse, M. T., Ferreira, P. C. L., Prasadan, A., Diaz, J. L., Zeng, X., Bellaver, B., Povala, G., Villemagne, V. L., Kamboh, M. I., Cohen, A. D., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01803-w · Cited by 13
Shim, G. H., Lau, E. C. Y., Huynh, A. L. H., Lu, C. Y., & Tan, E. C. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102981 · Cited by 19
Boada, M., KIPROV, D. D., Anaya, F., López, O. L., Núñez, L., Olazarán, J., Lima, J., Grifols, C., Barceló, M., Rohe, R., et al. (2022) · Journal of Clinical Apheresis · doi:10.1002/jca.22026 · Cited by 14
Mazer, N. A., Hofmann, C., Lott, D., Gieschke, R., Klein, G., Boess, F., Grimm, H. P., Kerchner, G. A., Baudler, M., Smith, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12877 · Cited by 14
“15”
Tau PET Visual Reads: Research and Clinical Applications and Future Directions
Soleimani‐Meigooni, D. N., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265017 · Cited by 11
“In AD clinical trials, tau PET is increasingly being used in participant selection, pretreatment staging, and measurement of treatment response (6).”
MethodShifting the balance: soluble ADAM10 as a potential treatment for Alzheimer's disease
Hershkovits, A. S., Gelley, S., Hanna, R., Kleifeld, O., Shulman, A., & Fishman, A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1171123 · Cited by 13
“These potential disease-modifying treatments are antibodies characterized by their ability to target toxic Aβ oligomers and plaques, thus stimulating the immune system to reduce their levels (Sevigny et al., 2016; Tolar et al., 2020a; Mintun et al., 2021; Swanson et al., 2021).”
BackgroundContextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer’s Disease
Lalwani, R. C., Volmar, C., Wahlestedt, C., Webster, K. A., & Shehadeh, L. A. (2023) · Biomedicines · doi:10.3390/biomedicines11123232 · Cited by 15
“Donanemab, an antibody that targets a modified form of deposited A β , is expected to receive FDA approval by the end of 2023 [12,150].”
BackgroundBeveridge, J., Kaniecki, E., Naidu, A., Silverglate, B., & Grossberg, G. T. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2304059 · Cited by 13
“In January 2023, the FDA issued a complete response letter requesting a minimum of 100 patients be treated with donanemab for at least 12 months; this had not been achieved due to many patients completing treatment earlier than expected [28].”
BackgroundMethodInfluentialde Havenon, A., Gottesman, R. F., Willamson, J. D., Rost, N. S., Sharma, R., Li, V., Littig, L., Stulberg, E. L., Falcone, G. J., Prabhakaran, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14126 · Cited by 13
Monane, M., Maraganore, D. M., Carlile, R. M., Johnson, K. G., Merrill, D. A., Gitelman, D. R., Sharlin, K. S., VandeVrede, L. A., George, K. K., Wang, J., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15020167 · Cited by 11
Kuriyama, M., Wang, C. F., Nagase, T., Sohma, Y., Kanai, M., Hori, Y., & Tomita, T. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00548 · Cited by 12
“Several antibodies have demonstrated ef fi cacy in clinical trials, including recently approved A β antibodies by the United States Food and Drug Administration (FDA) [5 – 7].”
Xu, J., Liu, B., Shang, G., Feng, Z., Yang, H., Chen, Y., Yu, X., & Mao, Z. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70285 · Cited by 13
Nyongesa, C. A., Hogarth, M. A., & Pa, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251339756 · Cited by 16
“2,3 Consequently, early detection still remains one of the most critical treatments in dementia care as it can offer the potential to delay or even prevent the onset of symptoms.”
Wang, D., Chernov, A. V., Lam, R., Wang, H., Li, W., Li, X., Duong, T., Wang, S., & Head, B. P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02258-z · Cited by 11
Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis
Whitfield, J. F., Rennie, K., & Chakravarthy, B. (2023) · Cells · doi:10.3390/cells12121618 · Cited by 12
Nowrangi, M. A., Outen, J. D., Kim, J., Avramopoulos, D., Lyketsos, C. G., & Rosenberg, P. B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221247 · Cited by 12
Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials
Scott, I. A. (2024) · Age and Ageing · doi:10.1093/ageing/afae023 · Cited by 12
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 13
Still grasping at straws: donanemab in Alzheimer’s disease
Doggrell, S. A. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1948010 · Cited by 12
“Only 20% of subjects assessed for eligibility were enrolled with the main reasons for screen failure being tau PET result (30%), MMSE or lack of historical tau PET (18%), and the CogState Brief Battery (17%) [1].”
BackgroundInfluentialSemorinemab in Mild-to-Moderate Alzheimer Disease
Edland, S. D., & Llibre‐Guerra, J. J. (2023) · Neurology · doi:10.1212/wnl.0000000000207861 · Cited by 11
Zhang, L., Du, X., Yang, C., Gong, H., Zhang, M., Han, Y., & Luo, H. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138239 · Cited by 11
New Approaches to the Treatment of Alzheimer’s Disease
Kruk-Słomka, M., Kuceł, D., Małysz, M., Machnikowska, A., Orzelska‐Górka, J., & Biała, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081117 · Cited by 14
“In EU countries, an application for the registration of donanemab was submitted in late 2024, with a regulatory decision by EMA expected in late 2025 [12,24,31,34] (Table 1).”
Chen, D., Chen, Q., Qin, X., Tong, P., Peng, L., Zhang, T., & Xia, C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1209863 · Cited by 11
The amyloid-β peptide: Guilty as charged?
Murphy, M. P., Buzinova, V. A., & Johnson, C. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166945 · Cited by 14
Rahman, M. S., Harrison, E., Biggs, H., Seikus, C., Elliott, P., Breen, G. D., Kingston, N., Bradley, J. R., Hill, S. M., Tom, B. D. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02960-5 · Cited by 15
“3 and 4), we conducted two genome-wide association studies (GWAS) to identify known or novel genetic loci determining general cognitive ability.”
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s
Song, T., Wang, Y., Silverglate, B., & Grossberg, G. T. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2357637 · Cited by 14
“Investigations into the safety profile of dona-nemab did not report any difference in deaths or serious adverse events that were related to the drug [26,32].”
BackgroundInfluentialGeerts, H., Bergeler, S., Walker, M., Rose, R. H., & van der Graaf, P. H. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12474 · Cited by 14
Lee, D. D., Antonsdottir, I. M., Clark, E. D., & Porsteinsson, A. P. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2360069 · Cited by 11
“Depending on the medication, the current and anticipated agents are administered as intravenous infusions given over 1 h every 2–4 weeks for 72–74 weeks [9,23,26].”
BackgroundInfluentialToda, Y., Iwatsubo, T., NAKAMURA, Y., Matsuda, N., Miyata, M., Jin, M., Chen, T., Kuribayashi, K., Tian, Y., Hughes, R. A., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.106 · Cited by 13
“Similar findings were observed previously in other studies of amyloid-targeting monoclonal antibodies (12, 15, 37-40).”
ResultDiagnosis and Management of Progressive Corticobasal Syndrome
Nouh, C. D., & Younes, K. (2024) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00797-4 · Cited by 14
“…and the reduction of amyloid with now 2 FDA approved amyloid therapies (aducanumab and lecanemab) and positive new phase 3 clinical trial results for donanemab, though there are still some controversies around their clinical usefulness beyond amyloid plaques removal [104, 105, 106, 107, 108, 109].”
Chen, T., Hutchison, R. M., Rubel, C., Murphy, J., Xie, J., Montenigro, P. H., Cheng, W., Fraser, K. B., Dent, G. W., Hendrix, S., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.126 · Cited by 10
“As an example, the emergence of recent data from multiple clinical trials of anti-Aβ antibodies in early symptomatic AD (12, 13, 40, 47) has provided sufficient data for group-level correlation across therapeutic agents with a similar mechanism of action.”
MethodResultZedde, M., Grisendi, I., Assenza, F., Napoli, M., Moratti, C., Pavone, C., Bonacini, L., Cecco, G. D., D’Aniello, S., Pezzella, F. R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154382 · Cited by 14
“Additionally, similar transient sulcal alterations can occur without evidence of superficial siderosis or hemorrhage, likely due to protein-rich fluid leakage into the leptomeningeal space, known as ARIA E [101].”
BackgroundMechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review
Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 16
Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease
Vroom, M. M., & Dodart, J. (2024) · Vaccines · doi:10.3390/vaccines12090973 · Cited by 13
“Lecanemab and donanemab, both of which are anti-amyloid mAbs for AD, possess similar safety and efficacy profiles [27,33].”
Backgroundβ-Amyloids and Immune Responses Associated with Alzheimer’s Disease
Kolobova, E. A., Petrushanko, I. Y., Mitkevich, V. A., Makarov, A. А., & Grigorova, I. (2024) · Cells · doi:10.3390/cells13191624 · Cited by 11
“Although the safety of this drug has been questionable [198,199], Donanemab was recently approved for use by the United States Food and Drug Administration [200].”
BackgroundIntrathecal Immunoselective Nanopheresis for Alzheimer’s Disease: What and How? Why and When?
Menéndez‐González, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910632 · Cited by 10
Bakker, A., Rani, N., Mohs, R. C., & Gallagher, M. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70004 · Cited by 21
“…the MCI phase of AD 1 for lecanemab while an analysis of brain volume under donanemab treatment did not consider topography of earliest degeneration 33 and blood biomarkers show a more consistent effect on GFAP than NfL. 34 The findings reported here are limited by the relatively small number of…”
Brain Stimulation in Alzheimer’s Disease Trials
Benussi, A., & Borroni, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230535 · Cited by 13
Triumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Quispialaya, K. M., Therriault, J., Aliaga, A., Tissot, C., Servaes, S., Rahmouni, N., Karikari, T. K., Benedet, A. L., Ashton, N. J., Macedo, A. C., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16255 · Cited by 12
Loukou, S., Παπαντωνίου, Γ., Pantazaki, Α. A., & Tsolaki, M. (2024) · Neurology International · doi:10.3390/neurolint16060095 · Cited by 13
Cao, W., Zhu, B., Liu, Z., Jia, X.-T., Zhao, H., Gu, N., Chang, H., Xi, J., Li, R., Guo, K., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.029 · Cited by 14
Hammers, D. B., Eloyan, A., Taurone, A., Thangarajah, M., Gao, S., Beckett, L. A., Polsinelli, A. J., Kirby, K., Dage, J. L., Nudelman, K. N. H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14439 · Cited by 9
Self-citationYu, Z., Liu, J., Liu, Z., Liu, X., Tuo, J., Li, J., Tu, Y., Tan, Q., Ma, Y., Bai, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14402 · Cited by 13
“5,6 The immune system is primarily executor of cerebral A β clearance, suchasmononuclearphagocytesystem.”
Sun, K. T., & Mok, S. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00512 · Cited by 18
“However, an issue that has arisen with all three treatments is the presence of amyloid-related imaging abnormalities (ARIA) [76 – 78].”
Chu, C., Wang, Y., Wang, Y., Fowler, C. J., Zisis, G., Masters, C. L., Doecke, J. D., Goudey, B., Jin, L., Pan, Y., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.53756 · Cited by 13
Future Perspectives of NMDAR in CNS Disorders
Capó, T., Rebassa, J. B., Raïch, I., Lillo, J., Badia, P., Navarro, G., & Reyes‐Resina, I. (2025) · Molecules · doi:10.3390/molecules30040877 · Cited by 13
“It exhibits high selectivity for this epitope and does not bind to other A β species, thus presenting no off-target effects [61].”
Blood N-glycomics reveals individuals at risk for cognitive decline and Alzheimer’s disease
Zhou, R. Z., Gaunitz, S., Kirsebom, B., Lundin, B., Hellström, M., Jejcic, A., Sköldunger, A., Wimo, A. B., Winblad, B. G., Fladby, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105598 · Cited by 11
Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 13
“The approvals of new anti-A β therapies aducanumab (Sevigny et al., 2016), lecanemab (van Dyck et al., 2023; Swanson et al., 2021), and donanemab (Mintun et al., 2021; Sims et al., 2023), also demonstrate a need for models which allow for the study of potential adverse effects of such therapies,…”
Echeveste, B., Prieto, E., Guillén, E. F., Jimenez, A., Montoya‐Murillo, G., Villino‐Rodríguez, R. A., Riverol, M., & Arbizu, J. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07275-2 · Cited by 10
Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial
Kutzsche, J., Cosma, N. C., Kauselmann, G., Fenski, F., Bieniek, C., Bujnicki, T., Pils, M., Bannach, O., Willbold, D., & Peters, O. (2025) · Nature Communications · doi:10.1038/s41467-025-59295-z · Cited by 13
Cummings, J. L., Cohen, S., Murphy, J., Brothers, H. M., Nejati, M., Forrestal, F., de Moor, C., O'Gorman, J. T., Harrison, J., Jaeger, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70224 · Cited by 12
“36,37 Clinically meaningful analysis approaches such as these using adu-canumab data demonstrate how consistent clinical effects can be demonstrated across a variety of clinical outcomes, which span cognitive, functional, and neurobehavioral domains and differing analytical approaches.”
Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease
Singleton, E. H., Mattsson, N., Binette, A. P., Stomrud, E., Strandberg, O. T., Palmqvist, S., Ossenkoppele, R., & Hansson, O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70435 · Cited by 15
Challenges in realizing therapeutic antibody biosensing
Nagata, M., Wilson, E. D., Ikebukuro, K., & Sode, K. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.07.003 · Cited by 10
A human neuron Alzheimer’s disease model reveals barriers to senolytic translatability
Walton, C. C., Wang, E. Y., Lee, S., Siebrand, C. J., Bergo, N. J., Mayeri, Z., & Andersen, J. K. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01822-7 · Cited by 10
Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment
Yang, Y., Koo, M., & Kwak, Y. T. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1639924 · Cited by 10
“A similar pattern of worsening was observed in the TRAILBLAZER-ALZ 1 trial of donanemab (33).”
Targeting protein misfolding in Alzheimer’s disease: The emerging role of molecular chaperones
Sharma, A., Srivastava, S., Gupta, P., Sridhar, S. B., Tariq, M., Rao, G. K., Kumar, S., & Malik, T. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118531 · Cited by 15
Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer’s disease
Francis, E., Paylor, S., Van, C., Mathews, B., Sobhanian, M. J., Mansour, D. Z., Hennawi, G., & Brandt, N. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2556122 · Cited by 13
“Although the secondary outcomes were mixed, there was also a significant reduction in brain amyloid plaque load in the donanemab group [81].”
Liu, S., Min, Z., Liu, Y., Yang, X., Yan, H., Xu, H. E., Wu, Y., & Xu, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1656906 · Cited by 15
Hasan, M. F., & Trushina, E. V. (2022) · Brain Sciences · doi:10.3390/brainsci12050552 · Cited by 10
“Controversial [6,7] results of clinical trials on reducing Aβ [8,9] or pTau levels [3–5] refocused AD drug development.”
BackgroundVolloch, V., & Rits‐Volloch, S. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230037 · Cited by 11
“tiple cleavages within iA , a capacity enhanced in BACE1 by the Icelandic A PP mutation [82, 83], thus explaining its protection from AD and AACD, and suppressed in BACE2 by the Flemish A PP mutation [84], explaining its causative role in FAD.”
BackgroundUreidobenzenesulfonamides as Selective Carbonic Anhydrase I, IX, and XII Inhibitors
Denner, T. C., Angeli, A., Ferraroni, M., Supuran, C., & Csuk, R. (2023) · Molecules · doi:10.3390/molecules28237782 · Cited by 9
“Moreover and amyloid disease are interest lecanemab [23] and donanemab [24,25]) that were recently approved for the therapy of Alzheimer’s disease.”
BackgroundAn asiatic acid derived trisulfamate acts as a nanomolar inhibitor of human carbonic anhydrase VA
Denner, T. C., Heise, N. V., Serbian, I., Angeli, A., Supuran, C. T., & Csük, R. (2024) · Steroids · doi:10.1016/j.steroids.2024.109381 · Cited by 10
Wessels, A. M., Belger, M. A., Johnston, J. A., Yu, Y., Rentz, D. M., Dowsett, S. A., & Chandler, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220303 · Cited by 12
Self-citationSur, C., Adamczuk, K., Scott, D., Kost, J. T., Sampat, M. P., Buckley, C. J., Farrar, G., Newton, B., Suhy, J., Bennacef, I., et al. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01735-z · Cited by 10
“1 3 here, with a reduction in amyloid load over time in the anti-amyloid treatment groups and little or no corresponding increase in amyloid load over time in the placebo groups [41, 46, 47].”
Önnestam, K., Nilsson, B., Rother, M., Rein-Hedin, E., Bylund, J., Anderer, P., Kemethofer, M., Halldin, M. M., Sandin, J., & Segerdahl, M. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.89 · Cited by 10
“Recently, substantial progress has been made in the development of disease modification agents targeting the amyloid cascade (4, 5, 6) with the US Food and Drug Administration recently granting approvals for the antibodies aducanumab and lecanemab, as well as the expected filing of donanemab during…”
BackgroundNew Hope for Alzheimer's Disease
Vellas, B. J., & Aisen, P. S. S. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.26 · Cited by 12
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Estimating prevalence of early symptomatic Alzheimer's disease in the United States
Spargo, D., Zur, R., Lin, P., Synnott, P., Klein, E., & Hartry, A. (2023) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12497 · Cited by 9
Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons
Tohumeken, Ş., Deme, P., Yoo, S. W., Gupta, S., Rais, R., Slusher, B. S., & Haughey, N. J. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.105987 · Cited by 9
Tayeb, H. O., Khallaf, R. A., Muayqil, T. A., Alkeridy, W. A., Alibrahim, F. S., Alfaify, O. A., Qadi, N., & Tarazi, F. I. (2023) · Neurosciences · doi:10.17712/nsj.2023.2.20220133 · Cited by 9
Toyama, K., Spin, J. M., Tsao, P. S., Maruyama, K., Osawa, H., Mogi, M., & Takata, Y. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15911 · Cited by 9
“As described previously (Morioka et al., 2010), CAVI was measured using an automatic vascular screening system (VaSera VS 1500E, Fukuda Denshi).”
MethodNiazi, S. K., & Magoola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12040851 · Cited by 7
“Another monoclonal antibody, donanemab, was in the advanced stages of development for patients with early AD [19].”
BackgroundMethodBiomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease
Elghanam, Y., Purja, S., & Kim, E. Y. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240008 · Cited by 11
Burkhart, M. C., Lee, L. Y., Vaghari, D., Toh, A. Q., Chong, E. J. Y., Chen, C., Tiňo, P., & Kourtzi, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-60914-w · Cited by 14
“However, recent developments in drug discovery (e.g. 3,4 ) call for interventions earlier in the progression of disease 5,6 to enhance patient outcomes and aid future clinical trials.”
Wang, G., Wang, W., Mangal, B., Liao, Y., Schneider, L. S. S., Li, Y., Xiong, C., McDade, E., Kennedy, R., Bateman, R. J., et al. (2024) · Statistics in Medicine · doi:10.1002/sim.10089 · Cited by 11
Brain metabolites are associated with sleep architecture and cognitive functioning in older adults
Mueller, C., Nenert, R. E., Catiul, C., Pilkington, J., Szaflarski, J. P., & Amara, A. W. (2024) · Brain Communications · doi:10.1093/braincomms/fcae245 · Cited by 9
“24,25 Despite significant efforts, currently no pharmacological agents are available to reverse cognitive dysfunction in the elderly, although several recently developed drugs such as lecanemab 26 and donanemab 27 show promise for slowing cognitive decline in Alzheimer’s disease.”
BackgroundLee, J. H., Jia, J., Ji, Y., Kandiah, N., Kim, S., Mok, V., Pai, M., Senanarong, V., Suh, C. H., & Chen, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240684 · Cited by 11
“…therapy; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; MS, multiple sclerosis; PCP, primary care physician; PET, positron emission tomography; PI, prescribing information ity of cognitive impairment, 12 , 16 this may not be routinely used in primary clinical practice in Asia.”
BackgroundZhao, L., Ren, H., Su, J., Zhang, Q., He, D., Wu, T.-Y., Zhang, Y.-H., Wang, Z., & Fan, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156091 · Cited by 9
Advances and Challenges in Gene Therapy for Alzheimer’s Disease
Morroni, F., & Caccamo, A. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230783 · Cited by 8
Differences in setting of initial dementia diagnosis among fee‐for‐service Medicare beneficiaries
White, E. M., Bayer, T. A., Kosar, C. M., Santostefano, C. M., Muench, U., Oh, H., Gadbois, E. A., Gozalo, P. L., & Rahman, M. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19236 · Cited by 10
“Variation in hospital-and nursing home-based diagnoses across states is shown in Appendix eFigure 2.”
Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review
Silva, I. M. F., Franco, G. D. R. R., Gontijo, V. S., & Viegas, C. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00092 · Cited by 9
In Vivo Head-to-Head Comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in Alzheimer Disease
Olafson, E., Tonietto, M., Klein, G., Teng, E., Stephens, A. W., Russell, D., Pickthorn, K., & Bohorquez, S. M. S. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268623 · Cited by 10
Sin, M., Dage, J. L., Nho, K. T., Dowling, N. M., Seyfried, N. T., Bennett, D. A. A., Levey, A. I., & Ahmed, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041070 · Cited by 10
“…[12]; the initial treatment period (e.g., most instances of ARIA-E occur within the first 3 months of treatment); the type of antibody used [13–20]; higher dosages [11]; an ApoE E 4 genotype, with ApoE E 4 homozygotes posing the greatest risk [15,21–24]; and anti-thrombin use [12], have been…”
Remote cognitive tests predict neurodegenerative biomarkers in the Insight 46 cohort
Giovane, M. D., Giunchiglia, V., Cai, Z., Leoni, M., Street, R. E., Lu, K., Wong, A., Popham, M., Nicholas, J. M., Trender, W. R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14572 · Cited by 14
“3 Recent trials of anti-amyloid therapies showed beneficial effects in individuals with earlier symptomatic disease, 4,5 and these medications are now being trialed in asymptomatic individuals with AD pathology.”
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., Initiative, A. D. N., Weiner, M. W., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213490 · Cited by 10
Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil
Price, P. U., Heggie, R., Moriguti, J. C., & Pereira, L. R. L. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2025.101130 · Cited by 11
Frost, B. E., Rowe, J. B., Akinyemi, R., Abisambra, J. F., Ashton, N. J., Brendel, M., Buée, L., Butler, D., Carrillo, M. C., Chung, P. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70078 · Cited by 12
“The recent approvals of anti-amyloid immunotherapies 131–133 present both pragmatic and mechanistic grounds for considering such dual (or concurrent) amyloid/tau clinical trials.”
Jeon, S. Y., Wang, S., Roh, H. W., Kim, K. Y., Chang, Y. Y., Kim, E., Bae, J. N., & Ryu, S. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e215 · Cited by 9
Cogswell, P. M., Wiste, H. J., Therneau, T. M., Griswold, M. E., Mattsson, N., Palmqvist, S., Binette, A. P., Stomrud, E., Bateman, R. J., Barthélemy, N. R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70625 · Cited by 11
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 11
Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer’s Disease
Strużyńska, L., Adamiak, K., & Sidoryk‐Wȩgrzynowicz, M. (2026) · Biomolecules · doi:10.3390/biom16040595 · Cited by 9
Thakur, A., Rana, M., Vanjani, S., Liou, K.-C., Taliyan, R., Nepali, K., & Yang, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70047 · Cited by 12
Imbimbo, B. P., Triaca, V., Imbimbo, C., & Nisticò, R. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.363185 · Cited by 10
“Although the FDA decision was widely contested (Nisticò and Borg, 2021), other two potent anti-Aβ monoclonal antibodies, donanemab (Mintun et al., 2021) and lecanemab (Swanson et al., 2021) have shown profound reducing effects in clearing brain amyloid plaques and encouraging results in Phase 2…”
BackgroundRomei, M. G., Leonard, B. C., Kim, I., Kim, H. S., & Lazar, G. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104685 · Cited by 10
Friends and Foes in Alzheimer’s Disease
Pauwels, E. K. J., & Boer, G. J. (2023) · Medical Principles and Practice · doi:10.1159/000534400 · Cited by 12
“A third antibody, donanemab [71] has not yet obtained this status.”
Background
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.